LEO1

RNA polymerase-associated protein LEO1 · Q8WVC0 · LEO1 on Sugi Atlas →

0 patent compounds predicted against LEO1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to LEO1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma PHASE1/PHASE2RECRUITING
Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants PHASE1/PHASE2SUSPENDED
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients PHASE1/PHASE2WITHDRAWN
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer PHASE2RECRUITING
Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma PHASE1COMPLETED
NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors PHASE1COMPLETED
Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects. PHASE1COMPLETED
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia PHASE1COMPLETED
A Vaccine Study for High Risk Cancers PHASE1WITHDRAWN
Dose Escalation Study of Immunomodulatory Nanoparticles PHASE1ACTIVE_NOT_RECRUITING
Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1 PHASE1COMPLETED
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS nanRECRUITING
Collection of Blood Samples for DNA in Motor Neuron Disease nanCOMPLETED
Amyotrophic Lateral Sclerosis (ALS) Families Project nanRECRUITING
MEHMO Natural History and Biomarkers nanRECRUITING
Genetics of Familial and Sporadic ALS nanCOMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
Gut Microbiome in Patients With Polycystic Ovary Syndrome nanUNKNOWN
Corrective Exercise and Rehabilitation in Fanconi Anemia: A Case Study nanCOMPLETED
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes nanRECRUITING
New Strategies of Genetic Study of Patients With Oculocutaneous Albinism nanCOMPLETED
Genetic Variants in Linear Localized Scleroderma nanCOMPLETED
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve nanUNKNOWN
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN
PCD New Gene Discovery nanCOMPLETED
Impact of Elastin Mediated Vascular Stiffness on End Organs nanCOMPLETED
Prospective Identification of Long QT Syndrome in Fetal Life nanCOMPLETED
The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study nanRECRUITING
Exome Evaluation in Patients Living With Diabetes Complicated by Charcot Neuroarthropathy. nanCOMPLETED
Investigation of Copy Number Variations and Genetic Variants in POI nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a LEO1 binder may also engage these)

ProteinNameSimilarity
Q5XJE5 1.000 Q5XJE5 →
Q641X2 1.000 Q641X2 →
Q6NYV9 0.998 Q6NYV9 →
Q52KV5 0.997 Q52KV5 →
Q5R4D6 0.997 Q5R4D6 →
Q3SWT4 0.992 Q3SWT4 →
Q505H7 0.991 Q505H7 →
IWS1 Protein IWS1 homolog 0.988 landscape →
Q04870 0.986 Q04870 →
Q8C1D8 0.986 Q8C1D8 →
Q9FNQ0 0.985 Q9FNQ0 →
Q94546 0.984 Q94546 →
P38439 0.982 P38439 →
Q6DE96 0.982 Q6DE96 →
Q9SU25 0.981 Q9SU25 →
F4ICK8 0.978 F4ICK8 →
Q5XHJ5 0.978 Q5XHJ5 →
Q9NQZ2 0.978 Q9NQZ2 →
Q93712 0.978 Q93712 →
Q54MB8 0.977 Q54MB8 →
Q9Y2W2 0.977 Q9Y2W2 →
Q3T160 0.977 Q3T160 →
A1D3N8 0.977 A1D3N8 →
A0A286Y9D1 0.977 A0A286Y9D1 →
Q9W062 0.977 Q9W062 →
U2SURP U2 snRNP-associated SURP motif-containing protein 0.976 landscape →
Q56P03 0.976 Q56P03 →
Q5TUF1 0.976 Q5TUF1 →
O13701 0.976 O13701 →
Q0V3E0 0.975 Q0V3E0 →